Cognizant collaborates with Boehringer Ingelheim to accelerate the medicinal therapies development

Uli Brӧdl, Senior Vice President, Global Clinical Development at Boehringer Ingelheim

Cognizant announced it is working with Boehringer Ingelheim, one of the leading research-driven biopharmaceutical company, to advance the speed and quality of medicinal therapy development. Leveraging the Veeva Development Cloud, Cognizant will help Boehringer Ingelheim to unify medicinal development processes and data into a connected technology ecosystem, enhancing collaboration across clinical, regulatory, and quality functions.

“Achieving an end-to-end platform to help speed the development of life-changing therapies has been an elusive goal for many organizations, and we’re making that vision a reality,” said Uli Brӧdl, Senior Vice President, Global Clinical Development at Boehringer Ingelheim. “Our collaborations with Cognizant and Veeva are empowering us to advance this important program that will positively impact patient lives.”

Branded as the “One Medicine Platform,” Boehringer Ingelheim’s connected ecosystem is expected to be one of the largest global implementations of Veeva technology. By bringing together Boehringer Ingelheim’s clinical, regulatory, and quality functions onto this unified platform simultaneously, this holistic approach is expected to increase interoperability and operational efficiencies.

Cognizant initiated the Boehringer Ingelheim engagement with an analysis of the biopharmaceutical manufacturer’s business and technology, followed by development of the program roadmap and agile methodology for system integration. Collaborating with Veeva, Cognizant is now implementing services, which include program management, system architecture and design, training, data migration, integration, testing and validation services. 

Srini Shankar, Global Head of Cognizant Life Sciences

“Utilizing advanced technologies to improve the quality and delivery of novel medicines is a must for innovative pharmaceutical companies, and Boehringer Ingelheim stands out for their forward thinking in pursuing development of the One Medicine Platform,” said Srini Shankar, Global Head of Cognizant Life Sciences. “Veeva has been recognized as one of the fastest growing life sciences technology companies, and Cognizant is a skilled system integrator with the expertise necessary to simultaneously implement multiple Veeva platforms. We are proud to be working together to set new precedents in the way clinical, regulatory, and quality functions come together to help accelerate the delivery of new life-saving therapies.”

Source

Some recent technological developments in the bio-pharma sector:

Tianlong unveils two new products for portable and on-site testing needs

Inotrem Receives Funding From the Crohn’s & Colitis Foundation

Lenovo collaborates with Novo Genomics to implement technologies in genomics

Cleveland Clinic and IBM unveil First Quantum Computer dedicated to healthcare research

RELATED ARTICLES

Recent News